MedTrace Logo

Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments

NCT04527601 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 885

Last updated 2020-10-08

No results posted yet for this study

Summary

This is a retrospective, observational study based on the consortium of the SafeBoosC-III randomised clinical trial. This study will evaluate if the number of admitted extremely preterm infants has decreased in the SafeBoosC-III departments during the global lockdown, and whether there is an association between the level of lockdown restrictions and change in the number of ELGAN admissions.

Conditions

  • Extreme Prematurity
  • Covid19

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Gorm Greisen, MD, Prof · Rigshospitalet, Denmark

Eligibility

Min Age
22 Weeks
Max Age
28 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-21
Primary Completion
2020-09-13
Completion
2020-09-13

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04527601 on ClinicalTrials.gov